Regression of diffuse large B-cell lymphoma after discontinuation of salazosulfapyridine
An 81-year-old man with a 3-year history of salazosulfapyridine (SASP) therapy for rheumatoid arthritis (RA) presented with pulmonary infiltrates and underwent computed tomography-guided biopsy. The histopathological and immunohistochemical evaluation confirmed the diagnosis of diffuse large B-cell lymphoma (DLBCL). He was recommended chemotherapy, which he refused. Due to the possibility of other iatrogenic immunodeficiency-associated lymphoproliferative disorders, SASP therapy was discontinued. SASP therapy withdrawal led to near-complete resolution of the lung infiltration shadows, and the serum soluble interleukin 2 receptor level returned to the normal range. This is the first report of a case of remission of DLBCL, following SASP therapy withdrawal in a patient with RA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Rinsho ketsueki] The Japanese journal of clinical hematology - 63(2022), 2 vom: 20., Seite 99-103 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Yoshinaga, Noriyoshi [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.03.2022 Date Revised 11.03.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.11406/rinketsu.63.99 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337953848 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337953848 | ||
| 003 | DE-627 | ||
| 005 | 20231225235603.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.11406/rinketsu.63.99 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1126.xml |
| 035 | |a (DE-627)NLM337953848 | ||
| 035 | |a (NLM)35264509 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Yoshinaga, Noriyoshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Regression of diffuse large B-cell lymphoma after discontinuation of salazosulfapyridine |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2022 | ||
| 500 | |a Date Revised 11.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a An 81-year-old man with a 3-year history of salazosulfapyridine (SASP) therapy for rheumatoid arthritis (RA) presented with pulmonary infiltrates and underwent computed tomography-guided biopsy. The histopathological and immunohistochemical evaluation confirmed the diagnosis of diffuse large B-cell lymphoma (DLBCL). He was recommended chemotherapy, which he refused. Due to the possibility of other iatrogenic immunodeficiency-associated lymphoproliferative disorders, SASP therapy was discontinued. SASP therapy withdrawal led to near-complete resolution of the lung infiltration shadows, and the serum soluble interleukin 2 receptor level returned to the normal range. This is the first report of a case of remission of DLBCL, following SASP therapy withdrawal in a patient with RA | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Diffuse large B-cell lymphoma | |
| 650 | 4 | |a Other iatrogenic immunodeficiency-associated lymphoproliferative disorders | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a Salazosulfapyridine | |
| 650 | 7 | |a Sulfasalazine |2 NLM | |
| 650 | 7 | |a 3XC8GUZ6CB |2 NLM | |
| 700 | 1 | |a Oka, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Asagoe, Kohsuke |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rinsho ketsueki] The Japanese journal of clinical hematology |d 1972 |g 63(2022), 2 vom: 20., Seite 99-103 |w (DE-627)NLM000222178 |x 0485-1439 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2022 |g number:2 |g day:20 |g pages:99-103 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.11406/rinketsu.63.99 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2022 |e 2 |b 20 |h 99-103 | ||